Unknown

Dataset Information

0

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.


ABSTRACT: This study compared initiation of insulin and other antihyperglycaemic agents (AHAs) with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. After 1 year, fewer participants treated with canagliflozin versus placebo initiated any AHA (7% vs. 16%), insulin (3% vs. 9%) or any non-insulin AHA (5% vs. 12%) (P?

SUBMITTER: Matthews DR 

PROVIDER: S-EPMC7693248 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.

Matthews David R DR   Wysham Carol C   Davies Melanie M   Slee April A   Alba Maria M   Lee Mary M   Perkovic Vlado V   Mahaffey Kenneth W KW   Neal Bruce B  

Diabetes, obesity & metabolism 20200824 11


This study compared initiation of insulin and other antihyperglycaemic agents (AHAs) with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. After 1 year, fewer participants treated with canagliflozin versus placebo initiated any AHA (7% vs. 16%), insulin (3% vs. 9%) or any non-insulin AHA (5% vs. 12%) (P < .001 for all); overall AHA initiation rates increased  ...[more]

Similar Datasets

| S-EPMC6509073 | biostudies-literature
| S-EPMC7609006 | biostudies-literature
| S-EPMC8279612 | biostudies-literature
| S-EPMC5777572 | biostudies-literature
| S-EPMC6731200 | biostudies-literature
| S-EPMC1131198 | biostudies-other
| S-EPMC6830803 | biostudies-literature
| S-EPMC7078821 | biostudies-literature
| S-EPMC8006652 | biostudies-literature
| S-EPMC10909678 | biostudies-literature